Benzimidazoles as Potent and Orally Active mGlu5 Receptor Antagonists with an Improved PK Profile
摘要:
A focused chemical optimization effort of a compound 1 based on metabolite elucidation is described, resulting in 15i, a highly potent and selective mGlu5 receptor antagonist with an improved pharmacokinetic profile compared to 1. Characterization of 15i in vivo in the fear potentiated startle (FPS) paradigm revealed a robust reduction of conditioned fear behavior. This effect nicely correlates with the rat brain pharmacokinetics.
The present invention relates to novel bi-aryl amines of formula (I) and to pharmaceutically acceptable prodrugs, salts, solvates, hydrates, and N-oxides thereof and to pharmaceutical compositions comprising them, methods of their use, and methods of their preparation.
[EN] The present invention relates to novel bi-aryl amines of formula (I) and to pharmaceutically acceptable prodrugs, salts, solvates, hydrates, and N-oxides thereof and to pharmaceutical compositions comprising them, methods of their use, and methods of their preparation. [FR] La présente invention concerne de nouvelles bi-aryle amines de formule (I) et leurs promédicaments, sels, solvates, hydrates et N-oxydes pharmaceutiquement acceptables, ainsi que des compositions pharmaceutiques les comprenant, leurs procédés d'utilisation et de préparation.
WO2007/113276
申请人:——
公开号:——
公开(公告)日:——
Benzimidazoles as Potent and Orally Active mGlu5 Receptor Antagonists with an Improved PK Profile
A focused chemical optimization effort of a compound 1 based on metabolite elucidation is described, resulting in 15i, a highly potent and selective mGlu5 receptor antagonist with an improved pharmacokinetic profile compared to 1. Characterization of 15i in vivo in the fear potentiated startle (FPS) paradigm revealed a robust reduction of conditioned fear behavior. This effect nicely correlates with the rat brain pharmacokinetics.